Keytruda (Pembrolizumab) Receives Supplemental FDA Approval for Efficacy

The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab) on June 6, 2025. This approval specifically addresses the efficacy of the drug, as indicated by the supplemental application.

What this means

This supplemental approval for Keytruda (pembrolizumab) regarding its efficacy reinforces the drug's established therapeutic profile. While the specific details of the expanded efficacy are not provided in the public record, such approvals typically signify a broadened scope of use or a stronger evidence base for existing indications. This development is important for clinicians and researchers as it confirms the FDA's ongoing evaluation and validation of pembrolizumab's effectiveness.

Source

The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA) website. The approval for supplemental application BLA 125514 S-183 for Keytruda (pembrolizumab) was recorded on June 6, 2025, on accessdata.fda.gov.